Hostname: page-component-78c5997874-fbnjt Total loading time: 0 Render date: 2024-11-20T00:25:55.706Z Has data issue: false hasContentIssue false
  • English
  • Français

The use of clozapine in South Manchester

Published online by Cambridge University Press:  02 January 2018

Alice Seabourne  and
Christopher S. Thomas
Alice Seabourne
Affiliation:
Department of Psychiatry, University Hospital of South Manchester, Manchester M20 8LR
Christopher S. Thomas
Affiliation:
Department of Psychiatry, University Hospital of South Manchester, Manchester M20 8LR
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

We describe a survey examining the use of clozapine in South Manchester since 1990. The aims were to determine the patient characteristics, type of illness, response to treatment and recording of this information. The case-notes of the first 25 patients to receive clozapine between 1990 and 1992 were audited. Guidelines about who should receive this drug and what objective assessments should be performed were agreed by the consultant group. The audit demonstrated that 24 patients suffered from chronic schizophrenia which had failed to respond to conventional neuroleptics. Routine mental state examinations were regularly performed but objective assessments using standardised rating scales were employed infrequently. Sixteen out of 25 improved on clozapine but at the end of 1992 only ten subjects were still receiving this drug. The majority had been discontinued because of side effects.

Type
Audit
Information
Psychiatric Bulletin , Volume 18 , Issue 10 , October 1994 , pp. 618 - 619
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
Copyright © Royal College of Psychiatrists, 1994

References

Burrell, M. F., Fewster, C. Szabadi, E. & Cashman, M. (1991) Clozapine-treated NMS. British Journal of Psychiatry, 158, 577.Google Scholar
Clozapine Study Group (1993) The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. British Journal of Psychiatry, 163, 150–154.Google Scholar
Kane, J., Honigfeld, G., Singer, J. & Meltzer, H. Y. (1988) Clozapine for treatment resistant schizophrenia: a double blind comparison with chlorpromazine. Archives of General Psychiatry, 48, 789–96.Google Scholar
King, D. J. & Mills, P. J. (1993) Clozapine: the Holywell experience with the first 24 patients. Irish Journal of Psychological Medicine, 10, 30–34.Google Scholar
Lukoff, D., Neuchterlein, K. H. & Ventura, J. (1986) Manual for Expanded Brief Psychiatric Rating Scale (BPRS). Schizophrenia Bulletin, 12, 594–602.Google Scholar
Meltzer, H. Y., Bastani, B., Young Kwon, K., Ramirez, L. P. et al (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. Psychopharmacology. 99, (Suppl.), 568–572.Google Scholar
Mortimer, A. M. (1991) Clozapine and schizophrenia. Schizophrenia Monitor, 1, 1–4.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.